Evidence map›Paper›PMID 40844731›Full record

ArticleInternational journal of clinical oncology2025

A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancer.

Taiju Ando, Yuko Oya, Yumi Tomiie, Kimio Ogawa, Tomoki Kuki, Yosuke Tanabe, Hisayuki Kato, Kazuyoshi Imaizumi, Yatsuka Hibi, Kenji Kawada

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Taiju AndoDepartment of Medical Oncology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. 81023003@fujita-hu.ac.jp.ORCID http://orcid.org/0009-0001-3009-0583
Yuko OyaDepartment of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan.
Yumi TomiieDepartment of Endocrine Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Kimio OgawaDepartment of Endocrine Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Tomoki KukiDepartment of Otolaryngology-Head and Neck Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Yosuke TanabeDepartment of Otolaryngology-Head and Neck Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Hisayuki KatoDepartment of Otolaryngology-Head and Neck Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Kazuyoshi ImaizumiDepartment of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan.
Yatsuka HibiDepartment of Endocrine Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Kenji KawadaDepartment of Medical Oncology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBRAF V600E mutation is a key oncogenic driver commonly found in papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC). Dabrafenib plus trametinib combination therapy targeting this mutation has shown promising activity in clinical trials. This study aimed to verify the real-world effectiveness of this combination therapy in patients with BRAF V600E-positive PTC and ATC.

methodsWe retrospectively investigated adult patients with BRAF V600E-positive PTC and ATC who were treated with dabrafenib plus trametinib at a single university hospital in Japan.

resultsBetween January 2024 and December 2024, 10 patients with PTC and 6 patients with ATC were identified, among whom 13 patients (81%) had been previously treated with lenvatinib. An objective response was observed in 5 patients with PTC (50%) and 4 patients with ATC (67%). The median progression-free survival and overall survival were not reached in patients with PTC, and were 2.7 months and 3.6 months, respectively, in patients with ATC. Partial regression of intracranial metastatic tumors was observed in 1 of the 2 patients with brain metastases at baseline. Rechallenge with another BRAF/MEK inhibitor combination therapy, encorafenib plus binimetinib, was attempted in 2 patients with ATC and demonstrated clinically meaningful responses.

conclusionsDabrafenib plus trametinib combination therapy demonstrated clinical effectiveness in patients with BRAF V600E-positive thyroid cancer, with response rates comparable to those observed in clinical trials. However, tumor shrinkage did not appear to translate into improved survival in patients with ATC, highlighting the limitations of current targeted therapies in managing this aggressive subtype.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsProto-Oncogene Proteins B-rafThyroid Cancer, PapillaryThyroid Carcinoma, AnaplasticThyroid NeoplasmsAdultAgedFemaleHumansImidazolesMaleMiddle AgedMutationOximesProgression-Free SurvivalPyridonesBRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibBRAF V600EDabrafenibThyroid cancerTrametinib

Identifiers

PMID40844731
PMCPMC12568863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.